Literature DB >> 6628517

Ketanserin in essential hypertension: effects during rest and exercise.

B Persson, T Hedner, G Berglund.   

Abstract

Ketanserin is a new, specific serotonin receptor blocking agent, which causes vasodilatation, presumably by an action on the vascular wall. The antihypertensive response to ketanserin 40 mg twice daily as monotherapy was assessed in 8 patients with essential hypertension. The investigation was an 8 week, double-blind, cross over study, which also included measurements during isometric (handgrip) and dynamic exercise (bicycle ergometry), as well as determination of plasma catecholamines and ketanserin. Ketanserin caused a reduction of supine and standing systolic and diastolic blood pressure (BP) during rest and a slight bradycardia. Although there was attenuation of the pressor response to handgrip, treatment with ketanserin did not really affect the changes in BP or heart rate during exercise, i.e. the base-line differences remained the same. There was no significant correlation between the effect on BP and the plasma level of ketanserin. The changes in BP produced by ketanserin showed little correlation with the initial levels of plasma catecholamines or with alterations in those levels. Although the results did not indicate direct interference by ketanserin with sympathetic tone, the lack of reflexogenic tachycardia, as well as the lack of increase in plasma noradrenaline during hand grip, indicates at least some modulation of autonomic function. It is concluded that ketanserin lowers BP in essential hypertension without interference with cardiovascular reflexes during standing or exercise, and that the compound may offer an alternative approach in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628517     DOI: 10.1007/bf01037939

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method.

Authors:  P Hjemdahl; M Daleskog; T Kahan
Journal:  Life Sci       Date:  1979-07-09       Impact factor: 5.037

2.  Indirect blood pressure and heart rate measured quickly without observer bias using a semi-automatic machine (auto-manometer)--response to isometric exercise in normal healthy males and its modification by beta-adrenoceptor blockade.

Authors:  G Nyberg
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Acute blood-pressure-lowering effect of ketanserin.

Authors:  J De Cree; H Verhaegen; J Symoens
Journal:  Lancet       Date:  1981-05-23       Impact factor: 79.321

4.  Mechanism of the hypotensive effect of ketanserin.

Authors:  J R Fozard
Journal:  J Cardiovasc Pharmacol       Date:  1982 Sep-Oct       Impact factor: 3.105

5.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

6.  High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine.

Authors:  P O Okonkwo; I W Reimann; R Woestenborghs; U Klotz
Journal:  J Chromatogr       Date:  1983-02-11

7.  Plasma noradrenaline correlates with alpha-adrenoreceptor-mediated vasoconstriction and blood pressure in patients with essential hypertension.

Authors:  W Kiowski; P Van Brummelen; F R Bühler
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

8.  Plasma noradrenaline, age and blood pressure: a population study.

Authors:  D H Jones; C A Hamilton; J L Reid
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

9.  Circulating catecholamine levels in human and experimental hypertension.

Authors:  J de Champlain; L Farley; D Cousineau; M R van Ameringen
Journal:  Circ Res       Date:  1976-02       Impact factor: 17.367

10.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

View more
  14 in total

1.  Does a selective 5-hydroxytryptamine antagonist (ICI 169, 369) lower blood pressure in hypertensive patients?

Authors:  A K Scott; P Roy-Chaudhury; J Webster; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Effect of the acute sublingual administration of ketanserin in hypertensive patients.

Authors:  G Aliberti; E D'Erasmo; C M Oddo; E Vecci
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

4.  Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study.

Authors:  C Bartoloni; P Dupont; H Feltkamp; C I Johnston; K Steinbach; H Zilcher; F Kaindl
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

6.  Pharmacokinetics of ketanserin in patients with essential hypertension.

Authors:  B Persson; A Pettersson; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Effect of ketanserin on cerebral blood flow autoregulation in healthy volunteers.

Authors:  J F Schmidt; K S Olsen; G Waldemar; B C Jørgensen; O B Paulson
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

8.  Controlled trial of ketanserin in hypertension.

Authors:  J C McGourty; J H Silas; K J Cowen
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

9.  Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat.

Authors:  K Gradin; A Pettersson; T Hedner; B Persson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

10.  Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.

Authors:  T Hedner; B Persson
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.